Published in Clin Exp Immunol on May 01, 2005
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis (2006) 1.59
Prednisone, lupus activity, and permanent organ damage. J Rheumatol (2009) 1.38
Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol (2009) 1.21
Stem cells in clinical practice: applications and warnings. J Exp Clin Cancer Res (2011) 1.06
Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets. Pathol Res Pract (2008) 0.89
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 43.47
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
Sequential therapies for proliferative lupus nephritis. N Engl J Med (2004) 5.96
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med (2000) 4.99
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med (1986) 4.01
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum (2002) 3.96
A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med (2000) 3.65
Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum (1998) 3.41
Humoral immune responses in CD40 ligand-deficient mice. J Exp Med (1994) 3.32
Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med (1995) 2.89
The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum (1995) 2.82
Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med (2001) 2.77
Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med (1994) 2.71
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood (2001) 2.59
An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum (2002) 2.54
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) (2001) 2.45
Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int (1997) 2.25
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum (2004) 2.23
Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med (1996) 2.17
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum (2003) 2.11
Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest (1996) 2.09
CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells. J Immunol (1991) 2.04
Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum (2001) 2.01
Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med (1993) 1.99
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus (1998) 1.93
Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol (1995) 1.89
Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest (1996) 1.86
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis (2002) 1.74
Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis (1998) 1.73
Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest (2003) 1.63
Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus (1995) 1.63
Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum (2002) 1.59
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum (2004) 1.51
Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood (2000) 1.47
Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol (1996) 1.42
Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant (1996) 1.41
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 1.39
Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum (1993) 1.38
Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol (1999) 1.34
The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest (1999) 1.33
Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol (1997) 1.32
Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol (1998) 1.32
Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol (2001) 1.27
Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol (1995) 1.24
Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus (2004) 1.23
Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis (2001) 1.22
LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum (2003) 1.21
Systemic lupus erythematosus in North American Indians: a population based study. J Rheumatol (2000) 1.21
Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med (1995) 1.19
Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus (1998) 1.19
Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus (2001) 1.18
Human B cell precursors proliferate and express CD23 after CD40 ligation. J Exp Med (1993) 1.18
Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch (1994) 1.17
Longterm followup of childhood lupus nephritis. J Rheumatol (2002) 1.16
Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis (1993) 1.16
Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis (2004) 1.13
Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum (1989) 1.12
Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (1992) 1.09
T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. J Immunol (1994) 1.08
Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum (1997) 1.04
Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)--relation to Th1- and Th2-derived cytokines. Clin Exp Immunol (1999) 1.02
Effect of pro-inflammatory/anti-inflammatory agents on cytokine secretion by peripheral blood mononuclear cells in rheumatoid arthritis and systemic lupus erythematosus. Autoimmunity (2003) 0.99
Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus (1997) 0.98
Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int (1997) 0.98
Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol (1998) 0.98
Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine (1998) 0.98
Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med (1984) 0.98
CD40 ligand expressed on B cells in the BXSB mouse model of systemic lupus erythematosus. J Immunol (1997) 0.95
Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis (1997) 0.93
Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol (2001) 0.91
Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum (2003) 0.90
The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus (2001) 0.90
Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol (1994) 0.90
The role of CD40 ligand in systemic lupus erythematosus. Lupus (2004) 0.90
Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum (2004) 0.89
Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol (1997) 0.89
Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone. Rheumatology (Oxford) (2001) 0.88
Peripheral blood lymphocytes in SLE--hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. J Autoimmun (1998) 0.88
Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) (2002) 0.88
Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol (1994) 0.88
Apoptosis and altered dendritic cell homeostasis in lupus nephritis are limited by anti-CD154 treatment. J Immunol (2001) 0.87
IL-1RA in refractory systemic lupus erythematosus. Lupus (2004) 0.86
Systematic analysis of sequences of anti-DNA antibodies--relevance to theories of origin and pathogenicity. Lupus (2002) 0.85
Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus. Scand J Rheumatol (2001) 0.85
Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron (1995) 0.84
High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol (1996) 0.83
Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus. Immunol Invest (1998) 0.82
Production of IL-1beta, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE. Autoimmunity (1999) 0.82
Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis (1997) 0.81
Pulse methylprednisolone in SLE. Clin Rheum Dis (1982) 0.79
Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) (2004) 0.79
Treatment of lupus interstitial lung disease with intravenous cyclophosphamide. Arthritis Rheum (1994) 0.78
Autologous stem cell transplantation for systemic lupus erythematosus. Lupus (2004) 0.78
Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus (1998) 0.77
Methylprednisolone pulse therapy for lupus nephritis: a followup study. Clin Exp Rheumatol (1985) 0.77
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med (1993) 3.35
Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum (1999) 2.99
Idiotypic cross-reactions of monoclonal human lupus autoantibodies. J Exp Med (1983) 2.96
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75
Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol (1995) 2.69
Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest (1997) 2.57
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.49
Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum (2000) 2.28
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Mixed connective tissue disease--goodbye to all that. Br J Rheumatol (1992) 2.11
Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med (1988) 2.09
Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet (1984) 2.08
Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) (2001) 1.96
Raised serum IgG and IgA antibodies to mycobacterial antigens in rheumatoid arthritis. Ann Rheum Dis (1989) 1.85
B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) (2005) 1.83
Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clin Immunol Immunopathol (1984) 1.76
Useful laboratory measurements in the management of systemic lupus erythematosus. Q J Med (1982) 1.68
B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum (2006) 1.65
Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int (1995) 1.63
Associates of health status in patients with systemic lupus erythematosus. J Rheumatol (1999) 1.62
B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis (2007) 1.62
A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) (1999) 1.60
Treatment adherence and clinical outcome in systemic lupus erythematosus. Rheumatology (Oxford) (2007) 1.59
Detection of cross-reactive anti-DNA antibody idiotypes on renal tissue-bound immunoglobulins from lupus patients. J Clin Invest (1985) 1.59
Measurement of anti-DNA antibodies: a reappraisal using five different methods. Ann Rheum Dis (1987) 1.53
Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. Arthritis Rheum (1984) 1.53
The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view. Br J Rheumatol (1995) 1.49
Elevated IgG antibody levels to the mycobacterial 65-kDa heat shock protein are characteristic of patients with rheumatoid arthritis. Scand J Immunol (1989) 1.49
The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol (1995) 1.49
Sjögren's syndrome: association with type-1 diabetes mellitus. Br J Rheumatol (1989) 1.48
Prevalence, serological features, response to treatment and outcome of critical peripheral ischaemia in a cohort of lupus patients. Rheumatology (Oxford) (2008) 1.48
Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum (1985) 1.48
Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) (2002) 1.47
Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet (1988) 1.46
The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. Rheumatology (Oxford) (1999) 1.45
Thyroid autoimmunity in systemic lupus erythematosus: the clinical significance of a fluctuating course. Br J Rheumatol (1995) 1.44
Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol (2001) 1.44
Aberrant control of galactosyltransferase in peripheral B lymphocytes and Epstein-Barr virus transformed B lymphoblasts from patients with rheumatoid arthritis. J Rheumatol (1993) 1.43
Muscle changes in ankylosing spondylitis. Br J Rheumatol (1983) 1.43
Anti-DNA antibodies in the primary antiphospholipid syndrome (PAPS) Br J Rheumatol (1993) 1.42
Systemic lupus erythematosus--disease activity, severity, treatment and costs. J Rheumatol (1994) 1.39
Muscle strength and pre-osteomalacia in vegetarian Asian women. Lancet (1982) 1.39
Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) (2003) 1.38
Research and training review of the use of LAS, LAT and flexible training positions. Rheumatology (Oxford) (2001) 1.38
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) (2002) 1.37
Mycobacteria and autoimmunity. Immunol Today (1988) 1.36
An immunohistological study of secondary Sjögren's syndrome. Ann Rheum Dis (1984) 1.36
Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (2001) 1.34
Characterization of polymyositis infiltrates using monoclonal antibodies to human leucocyte antigens. Clin Exp Immunol (1981) 1.33
SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol (1996) 1.30
Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjögren's syndrome (SS), and primary SS. J Rheumatol (1998) 1.30
Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. J Biol Chem (1999) 1.26
Cytokines and systemic lupus erythematosus. Ann Rheum Dis (2000) 1.26
Haematological manifestations of systemic lupus erythematosus. Blood Rev (1993) 1.25
Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) (2001) 1.25
Pregnancy outcome in adult-onset idiopathic inflammatory myopathy. Rheumatology (Oxford) (2003) 1.24
Monoclonal antibodies to human leucocyte antigens in polymyositis and muscular dystrophy. Clin Exp Immunol (1983) 1.24
Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) (2004) 1.24
The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford) (2004) 1.23
The mosaic of autoimmunity. Immunol Today (1989) 1.23
The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford) (2008) 1.22
Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology (Oxford) (2006) 1.22
Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis (2002) 1.21
Reduced B-cell galactosyltransferase activity in rheumatoid arthritis. Lancet (1987) 1.21
Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus (2009) 1.21
Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol (1999) 1.19
The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (1983) 1.18
Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol (1997) 1.18
Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol (2000) 1.17
Analysis of glycosylation changes in IgG using lectins. J Immunol Methods (1990) 1.17
Profile of autoantibodies in the serum of patients with tuberculosis, klebsiella and other gram-negative infections. Clin Exp Immunol (1987) 1.17
Detection of antibodies to total histones and their subfractions in systemic lupus erythematosus patients and their asymptomatic relatives. Arthritis Rheum (1987) 1.16
International consensus for a definition of disease flare in lupus. Lupus (2010) 1.16
C-reactive protein in sera from patients with systemic lupus erythematosus. J Rheumatol (1982) 1.16
Shared idiotypes are expressed on mouse and human anti-DNA autoantibodies. Immunology (1985) 1.15
The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun (1999) 1.15
Splenic involvement in rheumatic diseases. Semin Arthritis Rheum (1997) 1.15
Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis (2005) 1.14
In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost (2009) 1.13
Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study. Rheumatology (Oxford) (2004) 1.13
Fc gamma RIIa polymorphism in systemic lupus erythematosus (SLE): no association with disease. Clin Exp Immunol (1996) 1.13
The sera of patients with Klebsiella infections contain a common anti-DNA idiotype (16/6) Id and anti-polynucleotide activity. Clin Exp Immunol (1987) 1.12
Preliminary evidence for gut involvement in the pathogenesis of rheumatoid arthritis? Br J Rheumatol (1986) 1.12
A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum (1999) 1.11
Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J Clin Invest (1992) 1.11
Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology (Oxford) (2003) 1.11
Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significance. Arthritis Rheum (1995) 1.11
Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis (1996) 1.10
Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology (Oxford) (2000) 1.10
Studies on autoantibodies to poly (adenosine diphosphate-ribose) in SLE and other autoimmune diseases. Ann Rheum Dis (1982) 1.09
Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 1.09
The relationship of anti-DNA antibody idiotypes and anti-cardiolipin antibodies to disease activity in systemic lupus erythematosus. Medicine (Baltimore) (1986) 1.09
Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis (2005) 1.09
Surface expression of heat shock protein 90 by blood mononuclear cells from patients with systemic lupus erythematosus. J Autoimmun (1992) 1.08
An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol (1999) 1.08
Anti-Rnp antibodies in chronic liver diseases. Clin Exp Rheumatol (1988) 1.07
Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol (2005) 1.07
Immunisation of patients with rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis (1988) 1.07